GHRP-6 Mechanism of Action — Research Reference
Ghrelin receptor agonism, central appetite-stimulating signal via NPY/AgRP neurons, and the secondary cortisol/prolactin profile distinguishing GHRP-6 in research.
GHRP-6 Mechanism of Action — Research Reference
GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) was the first GHRP characterized in detail and remains a reference compound for ghrelin-receptor research. It is distinguished from ipamorelin and GHRP-2 by a prominent central appetite-stimulating signal.
Receptor Target
GHRP-6 is an agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a). The receptor is expressed on pituitary somatotropes and on hypothalamic neurons regulating appetite — both populations are engaged at GH-effective doses.
Signal Transduction
GHS-R1a activation by GHRP-6 produces:
- Gαq/PLC-β/IP3 → intracellular Ca²⁺ release on somatotropes → GH-vesicle exocytosis.
- Gαs/cAMP/PKA → potentiation of GHRH signalling.
- Central NPY/AgRP neuron activation in the arcuate nucleus → robust appetite stimulation (the defining behavioural signature of GHRP-6 in rodent models).
Pharmacokinetics
Subcutaneous GHRP-6 reaches peak plasma in 15–30 minutes with a half-life of approximately 20–30 minutes. The D-amino acid scaffold confers peptidase resistance similar to other GHRPs.
Cortisol and Prolactin Effect
Like GHRP-2, GHRP-6 cross-activates corticotrope and lactotrope populations, producing acute ACTH and prolactin elevation. The magnitude is generally similar to GHRP-2 in published comparative studies.
Why the Appetite Signal Matters in Research
GHRP-6's central orexigenic effect makes it the most-cited GHRP in feeding-behaviour and ghrelin-pathway research — distinct from its GH-releasing role. Researchers focused purely on GH-pulse studies typically prefer ipamorelin or GHRP-2 to avoid the confounding appetite signal.
Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption.
References
- Bowers CY, Momany F, Reynolds GA, et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology. 1980;106(3):663–667.
- Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660.
- Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000;141(11):4325–4328.
Related Research Materials
Parent Research Hubs
Related Research Articles
Semaglutide Mechanism of Action — Receptor, Signalling & Pharmacokinetics
Receptor pharmacology of the long-acting GLP-1 receptor agonist semaglutide: binding affinity, downstream Gαs/cAMP/PKA signalling, gastric emptying, central appetite circuits and albumin-anchored PK.
Tirzepatide Mechanism of Action — Dual GIP/GLP-1 Receptor Pharmacology
Receptor pharmacology of the dual GIP/GLP-1 receptor agonist tirzepatide: imbalanced agonism, downstream signalling differences from semaglutide, and the metabolic consequences of GIP arm activation.
BPC-157 Mechanism of Action — Angiogenesis, NO Pathway & Growth Factor Crosstalk
Proposed mechanisms of stable gastric pentadecapeptide BPC-157: VEGFR2 phosphorylation, nitric oxide pathway modulation, growth-factor crosstalk and gastrointestinal cytoprotection.